Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts... Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13 | -2.25303292894 | 5.77 | 6.01 | 5.39 | 21398 | 5.572236 | CS |
4 | 0.58 | 11.4624505929 | 5.06 | 7.2 | 5.02 | 63758 | 5.81567503 | CS |
12 | 2.17 | 62.5360230548 | 3.47 | 7.2 | 3.25 | 65358 | 4.93426449 | CS |
26 | 2.87 | 103.610108303 | 2.77 | 7.2 | 2.77 | 282974 | 3.90174391 | CS |
52 | -19.128 | -77.2286821705 | 24.768 | 27.3272 | 2.77 | 263706 | 7.37645766 | CS |
156 | -1770.36 | -99.6824324324 | 1776 | 2335.04 | 2.77 | 1601546 | 110.84944115 | CS |
260 | -1850.36 | -99.6961206897 | 1856 | 5888 | 2.77 | 1382812 | 1026.4903741 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales